Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

Two months after the last chemotherapy, Bianca Balti resumes her battle against cancer. Fresh from participating in the Milan ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...

New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...

Genomic analyses funded by the National Cancer Institute show that ovarian cancer mutations are nearly identical across ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.